<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01582048</url>
  </required_header>
  <id_info>
    <org_study_id>E:531/2011</org_study_id>
    <secondary_id>2011-002192-41</secondary_id>
    <nct_id>NCT01582048</nct_id>
  </id_info>
  <brief_title>Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning</brief_title>
  <official_title>Multicenter Phase II Study of Peritransplantation Immunosuppression Using ATG, Rituximab, Sirolimus and Mycophenolate Mofetil in Patient Receiving Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning With Fludarabine and Treosulfan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. med. Wolfgang Bethge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Neovii Biotech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Feasibility and toxicity of peritransplantation immunosuppression with ATG, sirolimus,&#xD;
      mycophenolate mofetil and rituximab in patients receiving mismatched allogeneic HCT after a&#xD;
      reduced intensity conditioning regimen with fludarabine/treosulfan&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow enrollment&#xD;
  </why_stopped>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">August 17, 2016</completion_date>
  <primary_completion_date type="Actual">August 17, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment related mortality</measure>
    <time_frame>12 months after HCT</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment related mortality</measure>
    <time_frame>24 months after HCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity according CTC of protocol on day 100</measure>
    <time_frame>on day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment on day 100</measure>
    <time_frame>on day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft versus host disease</measure>
    <time_frame>3 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections</measure>
    <time_frame>2 years after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution of CD3, CD3/CD4/CD8, CD56, CD19 cells</measure>
    <time_frame>3 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft versus host disease</measure>
    <time_frame>6 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>24 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease response</measure>
    <time_frame>12 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease response</measure>
    <time_frame>24 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution of CD3, CD3/CD4/CD8, CD56, CD19 cells</measure>
    <time_frame>6 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution of CD3, CD3/CD4/CD8, CD56, CD19 cells</measure>
    <time_frame>12 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution of CD3, CD3/CD4/CD8, CD56, CD19 cells</measure>
    <time_frame>24 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft versus host disease</measure>
    <time_frame>12 months after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft versus host disease</measure>
    <time_frame>24 months after HCT</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">9</enrollment>
  <condition>Patients Receiving Mismatched Allogeneic HCT</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>immunosuppression</intervention_name>
    <description>Conditioning with treosulfan 14 g/m2 day -6 to -4, fludarabine 30 mg/m2/24h day-6 to -2, ATG-Fresenius 20 mg/kg day -4 to -2, rituximab 500 mg/m2 day -1. Unmanipulated PBSC day 0. Postgrafting immunosuppression with mycophenolate mofetil (15 mg/kg TID) and sirolimus (2 mg QD).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled for mismatched allogeneic HCT&#xD;
&#xD;
          -  Unrelated donor with maximal 2 antigen or allelic mismatches in HLA-I or HLA-II&#xD;
&#xD;
          -  Age &gt;=75, &gt;=18 years&#xD;
&#xD;
          -  Patients Age &lt;=50 if a HCT-CI score &gt; 2 [acc. to Sorror et al., 2005]&#xD;
&#xD;
          -  Karnofsky Index &gt;60%&#xD;
&#xD;
          -  Patients with:&#xD;
&#xD;
               -  Acute myeloid leukemia in CR (&lt;5% blasts)&#xD;
&#xD;
               -  Acute lymphoblastic leukemia in CR (&lt; 5% blasts)&#xD;
&#xD;
               -  Myelodysplastic syndrome with up to 20% blasts&#xD;
&#xD;
               -  Osteomyelofibrosis&#xD;
&#xD;
               -  Chronic lymphocytic leukemia&#xD;
&#xD;
               -  High grade Non-Hodgkin Lymphoma in CR or PR&#xD;
&#xD;
               -  Low grad Non-Hodgkin Lymphoma in CR or PR&#xD;
&#xD;
               -  M. Hodgkin in CR or PR&#xD;
&#xD;
               -  Chronic myeloid leukaemia in chronic phase or CR of blast crisis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with &gt;5% blasts in BM at the time of transplantation&#xD;
&#xD;
          -  Progressive or chemorefractory disease&#xD;
&#xD;
          -  Less than 3 months after preceding HCT&#xD;
&#xD;
          -  CNS involvement with disease&#xD;
&#xD;
          -  Fungal infections with radiological progression after receipt of amphotericin B or&#xD;
             active triazole for greater than 1 month.&#xD;
&#xD;
          -  Liver function abnormalities with bilirubin &gt;2 mg/dL and elevation of transaminases&#xD;
             higher 2x upper limit of normal.&#xD;
&#xD;
          -  Chronic active viral hepatitis&#xD;
&#xD;
          -  Ejection fraction &lt;40 % on echocardiography&#xD;
&#xD;
          -  Patients with &gt; grade II hypertension by CTC criteria&#xD;
&#xD;
          -  Creatinine clearance &lt;50 ml/min&#xD;
&#xD;
          -  Proteinuria &gt;800 mg/24 h&#xD;
&#xD;
          -  Respiratory failure necessitating supplemental oxygen or DLCO &lt;30%&#xD;
&#xD;
          -  Allergy against murine antibodies&#xD;
&#xD;
          -  Known allergy/intolerance against sirolimus or one of it's excipients&#xD;
&#xD;
          -  HIV-Infection&#xD;
&#xD;
          -  Female patients who are pregnant or breast feeding, or adults of reproductive&#xD;
             potential not employing an effective method of birth control during study treatment&#xD;
             and for at least 12 months thereafter. (Women of childbearing potential must have a&#xD;
             negative serum pregnancy test at study entry)&#xD;
&#xD;
          -  Concurrent severe and/or uncontrolled medical disease (e.g. uncontrolled diabetes,&#xD;
             congestive heart failure, myocardial infarction within 6 months prior to the study,&#xD;
             unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled&#xD;
             infection) which could compromise participation in the study&#xD;
&#xD;
          -  Patients with a history of psychiatric illness or condition which could interfere with&#xD;
             their ability to understand the requirements of the study (this includes&#xD;
             alcoholism/drug addiction)&#xD;
&#xD;
          -  Patients unwilling or unable to comply with the protocol&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Enrollment in an other trial interfering with the endpoints of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang A Bethge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center University Hospital of Tuebingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hematology/Oncology Medical Center University Hospital of Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>D-55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bone Marrow Transplantation Unit Medical Center University Hospital of Nuernberg</name>
      <address>
        <city>Nuernberg</city>
        <zip>D-90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology/Oncology Medical Center University Hospital of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BMT-Unit Deutsche Klinik f√ºr Diagnostik</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>April 16, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Wolfgang Bethge</investigator_full_name>
    <investigator_title>Associate Professor Hematology/Oncology</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

